#China Pulmonary Function Testing Systems Market | Explore Tumblr posts and blogs

researchinhealthcare · 3 years ago

Text

Lung Function Tests Market growing at a CAGR of 5.7% By 2022 | Industry Analysis, Size Estimation, Top Company Profile, Key Regions

Lung Function Tests Market Highlights :

It comprises of tests such as spirometry, gas diffusion test, body plethysmography, bronchial provocation test, and others.

Lung function tests also determine the whether the lungs are working properly, and their capacity to carry out respiration, thus making it necessary to identify the mode of treatment, and administration of drugs.

Prevalence of asthma is on the rise across the globe, especially in the developing countries. The market is driven by the increasing prevalence of respiratory diseases in urban areas for developing countries, and rising geriatric population. Additionally, increasing research and development activities, and technological advancements to identify the causes and risk factors for infectious lung diseases are fuelling the global lung function tests market growth.

The global lung function tests market is expected to grow at a CAGR of 5.7% during the forecast period.

Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Lung Function Tests market research report–Global forecast till 2023.”

Lung Function Tests Market Regional Analysis :

The lung function tests market is growing at a rapid pace in the Americas owing to emphasis on healthy lifestyle, and prevention of lung diseases. Also, increasing demand for technologically advanced diagnostic devices and the presence of major market players adding fuel to the growth of the market.

In Europe, the prevalence of allergic conditions is high, especially asthma, and allergy rhinitis. Rising prevalence of allergic conditions, and extensive research and development activities on the medical devices drive the market growth.

Get Free Sample Report @ https://www.marketresearchfuture.com/sample_request/4828

In Asia Pacific, the increasing prevalence of asthma, chronic obstructive pulmonary disease, poor healthcare system, and availability of diagnostic services leads the market growth. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence of gastrointestinal diseases in Asia Pacific was 15.8 and mortality was 11.7 per 100,000 person. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.

In the Middle East & Africa, the demand for medical devices is increasing for the diagnosis of chronic diseases such as COPD and others. Rising awareness about lung diseases among the adults, and development of the healthcare sector in the African countries also drive the growth of the market.

Lung Function Tests Market Segmentation :

The global lung function tests market is segmented on the basis of type, indication, devices, and end user.

On the basis of the type, the market is segmented into spirometry, gas diffusion test, body plethysmograph, bronchial provocation test, and others.

On the basis of the indication, the market is segmented into asthma, chronic bronchitis, respiratory infections, chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, lung cancer, and others.

On the basis of the devices, the market is segmented into spirometer, breath CO monitor, oscillometer, ergospirometer, dose controlled drug nebulizer, and others.

On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/lung-function-tests-market-4828

Major Players in Lung Function Tests Market :

Some of the key players in the global market are CareFusion Corporation (U.S.), MGC Diagnostic Corporation (U.S.), General Electric Company (U.S.), Perkin Elmer (U.S., Carestream Health, Inc. (U.S.), COSMED srl (Italy), NIHON KOHDEN CORPORATION (Japan), and others.

#Lung Function Tests Market Size #Lung Function Tests Market Share #Lung Function Tests Market Trends #Lung Function Tests Market Overview

1 note · View note

imrmarket · 3 years ago

Text

Pulmonary Function Testing Systems Market Witness Excellent Long-Term Growth

Pulmonary Functions Test System Market was valued at USD 2234.92 million in 2019 and is expected to reach USD 3557.15 million by the year 2026, at a CAGR of 6.93%.

The Global Pulmonary Functions Test System Market Analysis to 2028 is a specialized and in-depth study of the demand side platform software market with a special focus on the global market trend analysis. The report aims to provide an overview of the demand-side platform software market with detailed market segmentation by deployment type, organization size, and end-user. The global demand side platform software market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading demand platform software market players and offers key trends and opportunities in the demand platform software market.

The global Pulmonary Function Testing Systems Market research offers a comprehensive competitive landscape that considers both domestic and international competition. A review of the definition, categorization, competitiveness, factors, and current strategic movements is included in the report. The Pulmonary Function Testing Systems market is segmented by type, manufacturer, and application in the global market study. This study provides a more comprehensive insight of the current market size, industry landscape, expansion, and growth status for Pulmonary Function Testing Systems. It involves a market analysis of historical data and forecasts, as well as a set of reasonable assumptions and techniques.

The Major Players In The Pulmonary Functions Test System Market Include:

· CareFusion (BD),

· MGC Diagnostic,

· Data Sciences International

· Medline Industries

· Ganshorn

· 3M

· NSpire Health

· Schiller

· Morgan scientific

· CHEST

· NDD

· Vyaire Medical

· COSMED and many others

Market has segmented the global Pulmonary Functions Test System market on the basis of type, application, and region:

The Pulmonary Functions Test System market is segmented by type and application. Growth between segments over the period 2022-2028 provides accurate calculations and forecasts of revenue by type and application in terms of volume and value. This analysis can help you expand your business by targeting eligible niches.

By Type:

· Complete PFT Systems

· Portable PFT Systems

By Application:

· Chronic Obstructive Pulmonary Disease

· Asthma

· Chronic Shortness of Breath

· Restrictive Lung Disease

Download a Free Sample Copy of the Market Report: -

https://introspectivemarketresearch.com/request/399

By Regional Outlook (Revenue, USD Billion, 2017 – 2028)

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)

Asia-Pacific (China, India, Japan, Southeast Asia, Rest of APAC)

Middle East & Africa (GCC Countries, South Africa, Rest of MEA)

South America (Brazil, Argentina, Rest of South America)

Covid-19 Impact and Recovery Analysis on Industry:

The COVID-19 pandemic has had devastating effects on several industry verticals globally. To constrain the number of cases and slow the coronavirus spread, various public health guidelines were implemented in different countries across the globe. COVID-19 protocols ranging from declaring national emergency states, enforcing stay-at-home orders, closing nonessential business operations and schools, banning public gatherings, imposing curfews, distributing digital passes, and allowing police to restrict citizen movements within a country, as well as closing international borders. With the growing vaccination rate, governments are uplifting the protocols to give a boost to the stagnant economy. Like other industries, Pulmonary Functions Test System s Market have experienced slowdown the growth, however market is expected bounce back as restrictions are being lifted up by governments across the globe.

The research report includes an examination of various elements that contribute to market growth. It consists of market trends, restraints, and drivers that have a positive or negative impact on the market. This section also discusses the many sectors and applications that may have an impact on the market in the future. The data is based on current trends as well as historical milestones. This section also includes an analysis of worldwide production volume as well as production volume by type from 2022 to 2028.

If You Have Any Query of Pulmonary Functions Test System Market Report, Visit.

https://introspectivemarketresearch.com/inquiry/399

Report covered the major key points:

· Explore key findings of the overall market

· Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

· Market forecasts for a minimum of 7years, along with 5 years of historical data for all segments, sub-segments, and regions

· Market Segmentation caters to a thorough assessment of key segments with their market estimations

· Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

· Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

· Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

· Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Purchase This Report:

https://introspectivemarketresearch.com/checkout/?user=1&_sid=399

#Pulmonary Function Testing Systems Market Pulmonary Function Testing Systems Market Size Pulmonary Function Testing Systems Market Share Pul

0 notes

industryrecentdevelopment · 3 years ago

Text

Pulmonary Function Testing Systems Market Industry Trends

Global Pulmonary Function Testing Systems Market Research Report 2022-2028. The report offers an in-depth study and forecast of the industry covering a full overview of the market that will help communicate its clients and business building strategies. The report includes profiling of growth patterns of previous years, market shares, industry analysis, growth drivers, constraints, opportunities, challenges, and key market players. The CAGR forecast for the market is expressed as a percentage over a specific time period. The study also includes methods used by prominent players to outperform their competitors. Our report allows readers to understand the details of the market, latest trends, size and value forecasts, and various investment opportunities for manufacturers operating in global and regional markets.

According to this latest study, Pulmonary Function Testing Systems Market was valued at USD 2234.92 million in 2019 and is expected to reach USD 3557.15 million by the year 2026, at a CAGR of 6.93%.

Pulmonary function test plays a vital role in in the diagnosis of lung-related disorders such as COPD (Chronic Obstructive Pulmonary Disorders), asthma, and others. Pulmonary function testing provides insights and information about lung’s functioning, such as tidal volume, functional residual capacity, residual volume, total lung capacity, vital capacity, and peak expiratory flow rate amongst others.

Get Sample Reports : - https://introspectivemarketresearch.com/request/399

Pulmonary Function Testing Systems Market - Size, Competitive Landscape and Segmentation Analysis:

Pulmonary Function Testing Systems Market Reports provide a high-level overview of market segments by product type, applications, leading key players, and regions, as well as market statistics. The research insights focus on the impact of the Covid-19 epidemic on performance and offers a thorough examination of the current market and market dynamics. This crucial understanding of the report's objective can help you make better strategic decisions about investment markets by assessing elements that may affect current and future market circumstances. The leading key players in the Global and Regional market are summarized in a research to understand their future strategies for growth in the market.

Scope of the Pulmonary Function Testing Systems Market:

The main goal of this report is to help users understand the Pulmonary Function Testing Systems market in terms of its definition, segmentation, market potential, influential trends, and challenges facing the market. In-depth research and analysis took place while preparing the report. Readers will find this report very helpful to in-depth understanding of the market.

The key players covered in the Pulmonary Function Testing Systems market report is:

· CareFusion (BD

· MGC Diagnostic

· Data Sciences International

· Medline Industries

· Ganshorn

· 3M

· NSpire Health

· Schiller

· Morgan scientific

· CHEST

· NDD

· Vyaire Medical

· COSMED

Inquiry Before Purchase: - https://introspectivemarketresearch.com/inquiry/399

Market Segmentation Analysis By Product Type

· Complete PFT Systems

· Portable PFT Systems

Market Segmentation Analysis By Application:

· Chronic Obstructive Pulmonary Disease

· Asthma

· Chronic Shortness of Breath

· Restrictive Lung Disease

Market Segment by Regions and Countries Level Analysis:

· North America (U.S., Canada, Mexico)

· Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)

· Asia-Pacific (China, India, Japan, Southeast Asia, Rest of APAC)

· Middle East & Africa (GCC Countries, South Africa, Rest of MEA)

· South America (Brazil, Argentina, Rest of South America)

Covid-19 Impact and Recovery Analysis on Industry:

We've kept track of Covid-19's direct impact on this market as well as its indirect impact on other industries. During the analysis period, the impact of the Covid-19 pandemic on the market is predicted to be significant. From a worldwide and regional viewpoint, this report examines the influence of the pandemic on the Pulmonary Function Testing Systems industry. The study categorizes the Pulmonary Function Testing Systems industry by type, application, and consumer sector to determine market size, market features, and market growth. It also includes a thorough examination of the factors that influenced market development before and after the Covid-19 pandemic. In addition, the research did a pest analysis in the sector to investigate major influencers and entrance obstacles.

Customized Report: - https://introspectivemarketresearch.com/custom-research/399

The goal of the research report is to help develop business strategies that help meet the needs of end-user consumers and penetrate deeply into the market. Pulmonary Function Testing Systems market research also discusses significant market events that could have a positive or negative impact on the participants. It covers product offerings, revenue analysis, production capabilities, gross margins and many other important aspects that affect a company's profitability in the marketplace.

Some Important Questions Answered In The Report Are:

1.Which regions are projected to be the most dominant and growing regions in the near future?

2.What is the best cost optimization strategy you can adopt to succeed in the marketplace?

3.What are the key opportunities and threats that vendors may face during the forecast period?

4.What will be the market size, growth rate and market trends of Pulmonary Function Testing Systems Market during the forecast period?

Purchase the Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=399

Browse Others Reports:

https://www.digitaljournal.com/pr/sports-apparel-market-worth-270-25-billion-by-2028-exclusive-report-by-introspective-market-research

https://www.digitaljournal.com/pr/mattress-market-worth-us-79-04-billion-by-2028-market-size-share-forecasts-trends-analysis-report-with-covid-19-impact-by-introspective-market-research

#Pulmonary Function Testing Systems Market #Pulmonary Function Testing Systems Market share #Pulmonary Function Testing Systems Market size

0 notes

industryinsights · 3 years ago

Text

Lung Function Tests Market Size, Revenue Share, Growth Factors, Trends, Analysis & Forecast Till 2027

The global lung function tests market size is expected to grow at a CAGR of 5.7% during the forecast period.

Lung function tests are a part of routine diagnostic tests recommended by the healthcare provider. These tests are used to diagnose number of respiratory diseases such as chronic obstructive pulmonary disease (COPD), and allergic conditions such as asthma. It comprises of tests such as spirometry, gas diffusion test, body plethysmography, bronchial provocation test, and others. Lung function tests also determine the whether the lungs are working properly, and their capacity to carry out respiration, thus making it necessary to identify the mode of treatment, and administration of drugs.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4828

Major Players in Lung Function Tests Market:

Regional Analysis

Segmentation

The global lung function tests market is segmented on the basis of type, indication, devices, and end user.

On the basis of the type, the market is segmented into spirometry, gas diffusion test, body plethysmograph, bronchial provocation test, and others.

On the basis of the devices, the market is segmented into spirometer, breath CO monitor, oscillometer, ergospirometer, dose controlled drug nebulizer, and others.

On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/lung-function-tests-market-4828

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

0 notes

marketreportss · 3 years ago

Text

Pulmonary Functions Test System Market important Growth Factor with Regional Forecast, Top Vendors, and End User Analysis By 2028

The Final Report will cover the analysis of the Impact of Covid-19 on this industry.

Global Pulmonary Functions Test System Market Research Report 2022-2028. The report offers an in-depth study and forecast of the industry covering a full overview of the market that will help communicate its clients and business building strategies. The report includes profiling of growth patterns of previous years, market shares, industry analysis, growth drivers, constraints, opportunities, challenges, and key market players. The CAGR forecast for the market is expressed as a percentage over a specific time period. The study also includes methods used by prominent players to outperform their competitors. Our report allows readers to understand the details of the market, latest trends, size and value forecasts, and various investment opportunities for manufacturers operating in global and regional markets.

The global Pulmonary Functions Test System market provides qualitative and quantitative information on growth rate, market segmentation, market size, future trends and regional prospects. The research study represents a modern perspective aimed at securing the future potential of the Pulmonary Functions Test System market. This report analyzes and evaluates the latest prospects for the new retail space, as well as the general and future market performance of Covid-19. In addition, this report provides a detailed overview of competition between some industries and others.

According to this latest study, Pulmonary Functions Test System Market was valued at USD 2234.92 million in 2019 and is expected to reach USD 3557.15 million by the year 2026, at a CAGR of 6.93%.

Pulmonary Functions Test System Market - Size, Competitive Landscape and Segmentation Analysis:

Pulmonary Functions Test System Market Reports provide a high-level overview of market segments by product type, applications, leading key players, and regions, as well as market statistics. The research insights focus on the impact of the Covid-19 epidemic on performance and offers a thorough examination of the current market and market dynamics. This crucial understanding of the report's objective can help you make better strategic decisions about investment markets by assessing elements that may affect current and future market circumstances. The leading key players in the Global and Regional market are summarized in a research to understand their future strategies for growth in the market.

Scope of the Pulmonary Functions Test System Market:

The main goal of this report is to help users understand the Pulmonary Functions Test System market in terms of its definition, segmentation, market potential, influential trends, and challenges facing the market. In-depth research and analysis took place while preparing the report. Readers will find this report very helpful to in-depth understanding of the market.

The key players covered in the Pulmonary Functions Test System market report is:

· CareFusion (BD),

· MGC Diagnostic,

· Data Sciences International

· Medline Industries

· Ganshorn

· 3M

· NSpire Health

· Schiller

· Morgan scientific

· CHEST

· NDD

· Vyaire Medical

· COSMED

Market Segmentation Analysis By Product Type

· Complete PFT Systems

· Portable PFT Systems

Market Segmentation Analysis By Application:

· Chronic Obstructive Pulmonary Disease

· Asthma

· Chronic Shortness of Breath

· Restrictive Lung Disease

Market Segment by Regions and Countries Level Analysis:

· North America (U.S., Canada, Mexico)

· Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)

· Asia-Pacific (China, India, Japan, Southeast Asia, Rest of APAC)

· Middle East & Africa (GCC Countries, South Africa, Rest of MEA)

· South America (Brazil, Argentina, Rest of South America)

Covid-19 Impact and Recovery Analysis on Industry:

We've kept track of Covid-19's direct impact on this market as well as its indirect impact on other industries. During the analysis period, the impact of the Covid-19 pandemic on the market is predicted to be significant. From a worldwide and regional viewpoint, this report examines the influence of the pandemic on the Pulmonary Functions Test System industry. The study categorizes the Pulmonary Functions Test System industry by type, application, and consumer sector to determine market size, market features, and market growth. It also includes a thorough examination of the factors that influenced market development before and after the Covid-19 pandemic. In addition, the research did a pest analysis in the sector to investigate major influencers and entrance obstacles.

The goal of the research report is to help develop business strategies that help meet the needs of end-user consumers and penetrate deeply into the market. Pulmonary Functions Test System market research also discusses significant market events that could have a positive or negative impact on the participants. It covers product offerings, revenue analysis, production capabilities, gross margins and many other important aspects that affect a company's profitability in the marketplace.

Some Important Questions Answered In The Report Are:

1.Which regions are projected to be the most dominant and growing regions in the near future?

2.What is the best cost optimization strategy you can adopt to succeed in the marketplace?

3.What are the key opportunities and threats that vendors may face during the forecast period?

4.What will be the market size, growth rate and market trends of Pulmonary Functions Test System Market during the forecast period?

#Pulmonary Function Testing Systems Market #Pulmonary Function Testing Systems Market Size #Pulmonary Function Testing Systems Market Share #Pulmonary Function Testing Systems Market Growth

0 notes

latest-market-insights · 3 years ago

Text

Pulmonary Function Testing Systems Market 2023 | Business Opportunity, Growth Strategies & Forecast Report By 2028

The Global Pulmonary Function Testing Systems Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. The Pulmonary Function Testing Systems industry growth avenues are deeply supported by exhaustive research by the top analysts of the industry. The report starts with the executive summary, followed by a value chain and marketing channels study. The report then estimates the CAGR and market revenue of the global and regional segments.

Base Year: 2021

Estimated Year: 2022

Forecast years: 2023 to 2028

The report classifies the market into different segments based on type and product. These segments are studied in detail, incorporating the market estimates and forecasts at regional and country levels. The segment analysis is helpful in understanding the growth areas and potential opportunities of the market.

Get | Download FREE Sample Report of Global Pulmonary Function Testing Systems Market @ https://www.decisiondatabases.com/contact/download-sample-17711

A special section is dedicated to the analysis of the impact of the COVID-19 pandemic on the growth of the Pulmonary Function Testing Systems market. The impact is closely studied in terms of production, import, export, and supply.

The report covers the complete competitive landscape of the Worldwide Pulmonary Function Testing Systems market with company profiles of key players such as:

Becton, Dickinson and Company.

COSMED

Ganshorn Medizin Electronic GmbH

Koninklijke Philips N.V

Medical Equipment Europe

MGC Diagnostics Corporatio

Morgan Scientific Inc.

nSpire Health, Inc.

Omron Healthcare, Inc.

Schiller AG

Want to add more Company Profiles to the Report? Write your Customized Requirements to us @ https://www.decisiondatabases.com/contact/get-custom-research-17711

Pulmonary Function Testing Systems Market Analysis by Test Type:

Spirometer

Peak Flow Meter

Pulmonary Function Testing Systems Market Analysis by Product Type:

Portable PFT Systems

Complete PFT Systems

Pulmonary Function Testing Systems Market Analysis by End-User:

Hospitals And Clinics

Physician Offices

Other

Pulmonary Function Testing Systems Market Analysis by Geography:

North America (USA, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Australia, South-East Asia, Rest of Asia-Pacific)

Latin America (Brazil, Argentina, Peru, Chile, Rest of Latin America)

The Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East and Africa)

Key questions answered in the report:

What is the expected growth of the Pulmonary Function Testing Systems market between 2023 to 2028?

Which application and type segment holds the maximum share in the Global Pulmonary Function Testing Systems market?

Which regional Pulmonary Function Testing Systems market shows the highest growth CAGR between 2023 to 2028?

What are the opportunities and challenges currently faced by the Pulmonary Function Testing Systems market?

Who are the leading market players and what are their Strengths, Weakness, Opportunities, and Threats (SWOT)?

What business strategies are the competitors considering to stay in the Pulmonary Function Testing Systems market?

Purchase the Complete Global Pulmonary Function Testing Systems Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-17711

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: [email protected] Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

#Pulmonary Function Testing Systems Market #Pulmonary Function Testing Systems Market Report #Pulmonary Function Testing Systems Market Size

0 notes

gb9525295 · 4 years ago

Text

What is Parylene Overview ?

Parylene is the trade name of a synthetic polymer whose basic ingredient is a mixture of pyridine and pyrrolidine-6 headings. A group of compounds comprising this polymer have been found to be capable of improving lung function in mice and rats. This article focuses on Parylene Market Research and analysis data. The Global Parylene Market is one of the leading markets in the world in which millions of dollars are traded each day.

As the title of this article suggests, Parylene has been used for the treatment of cancer for many years. In the past decade or so Parylene has developed into an increasingly popular alternative cancer fighting drug due to its remarkable oral administration and its anti-cancer activity. It is primarily used to treat bladder and lung cancers with high success rates. The drug has also shown promise as an effective treatment for osteoporosis. Parylene displays chemo-identical properties with other drugs like chemotherapy drugs (such as carboplatin, cisplatin) and non-carcinogens (such as chlorination). While these features distinguish it from its primary competitors, Parylene continues to confound researchers with its effects on multiple biological pathways and mechanisms.

The focus of this article is Parylene's ability to modulate the expression of genes through the promoter, implying that it may be useful in treating lung cancer and other pulmonary disorders. A study conducted by the National Institute on Drug Abuse (NIDA) compared Parylene with systemic chemotherapy (adhesives), sulfasalazine, methotrexate and tricyclic anti-cancer agents. The NIDA report concluded that Parylene has distinct characteristics that set it apart from existing treatments for these types of cancer. One of the distinctive characteristics of Parylene was the ability to regulate gene expression in a manner similar to anti-tumor drugs (such as carboplatin, cisplatin and methotrexate).

When a patient with a type A cell lung tumor or alcoholic hepatitis takes Parylene, it stimulates the thyroid hormone to induce cells to tumors and proliferation. This effect is believed to be due to the induction of a cellular response that results in increased numbers of lung cancer cells. However, the exact mechanism underlying this effect is not known. In another study, lung cancer cells were grown in culture without Parylene but with a control substance, then treated with Parylene and the cancer cells grew to similar numbers seen with Parylene alone. These findings provide strong evidence that Parylene, when administered via oral spray, has the ability to control gene expression in lung cancer cells.

Like many cancer drugs, Parylene works by increasing oxygenation to tumors while blocking the production of amino acids that promote DNA mutation in cancer cells. Parylene also binds with free radicals and prevents them from damaging healthy cells. It was later discovered that Parylene can also protect against certain cancers; therefore, Parylene research and development now center on other aspects such as prevention of melanoma and pancreatic cancer.

Parylene, like all chemicals that inhibit enzymes, depletes the supply of oxygen to tumors while at the same time promoting proliferation of cancer cells. This oxygen deprivation causes severe cellular damage that is conducive to tumor growth. Cancer researchers are currently testing other compounds for treatment and hope that one of them will work better than Parylene. One promising compound is called azelaic acid, which inhibits matrix metalloproteinase (MMP) enzymes. Azelaic acid has been shown to reduce tumor growth in human lymphomas and breast cancers.

Parylene and its derivatives have shown very positive effects on patients with certain forms of cancer. Some of the early studies have indicated that Parylene and Dithiaoctanediol can help alleviate some symptoms of advanced cancers. In one study, Parylene significantly reduced tumor size and increased patient survival rate. In another study, Parylene reduced the spread of melanoma. However, more studies are needed to confirm these results.

The side effects of Parylene, however, are quite serious. In one study, researchers found that patients who took Parylene but not their standard doses had more complications due to their cancer. These included impotence, erectile dysfunction and decreased libido. Parylene and its derivatives are also linked to high blood pressure and stroke. Parylene may also cause sudden death. Therefore, people who use Parylene should consult with their doctor before taking this or any other drugs.

Summary

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Parylene market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Parylene market segmented into

Invasive

Non-invasive

Based on the end-use, the global Parylene market classified into

Heart Failure Treatment

Other Disease Treatment

Based on geography, the global Parylene market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Noninvasive Medical Technologies

Medtronic

Sensible Medical

0 notes

jesse-pinkman123 · 4 years ago

Text

Hemostasis Diagnostics Market Size Share Trends Forecast 2026

North America is the key growth engine in the global hemostasis diagnostics market

Regional segmentation of the Hemostasis Diagnostic Market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the Centre for Disease Control and Prevention in 2015, the number of people with hemophilia in the U.S. is estimated to be 20,000.

This positions North America as the most dominant region in the global hemostasis diagnostics market, owing to the rise in installed instruments leading to higher sales of reagents and support services. According to The European National Registry of Congenital Coagulopathies in 2017, the number of people identified with hemostasis has increased from 7000 in 2000 to over 11,000 in 2015.

Therefore, the European market is expected to grow steadily boosting the demand for hemostasis diagnostics. Significant growth of markets in India, China, and Brazil is registering due to the rise in health care expenditure, higher affordability, improving technical capabilities and economic development. These markets are expected to attract global companies for capitalizing on the hemostasis diagnostics market opportunities.

Hemostasis diagnostics help identify the hemostatic defects that cause excessive bleeding. Hemostasis is a process of slowing and stopping the blood flow to initiate wound healing after a vascular injury and is the key procedure acting in the first line of action adopted by the body. During the process, blood changes its form from the fluid state to the gelatinous state. Hemostasis is maintained in the body via three mechanisms namely vasoconstriction, platelet plug formation, and blood coagulation.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/434

The diagnosis helps predict the cause of excessive bleeding during the surgery, identifies hemostatic defects in patients with a history of excessive bleeding. Based on the research articles published by medical experts, the appropriate therapy to treat hemorrhage can be administered of fresh frozen plasma for coagulation defects, Von Willebrand factor concentrates for platelet function defects or antifibrinolytic agents for systemic fibrinolysis.

Rising prevalence of hemophilia drives the hemostasis diagnostics market globally

The critical nature of the procedure in the field of medicine and healthcare has gained a prominent position in the hemostasis diagnostics market. According to the National Hemophilia Foundation in 2012, the global incidence of hemophilia is estimated to be 400,000 people. The rise in the prevalence of genetically inherited disorders such as hemophilia, an increase in the number of surgeries and trauma patients, the surge in the usage of recombinant products are the collective factors driving the global market.

The growing technological advances in molecular diagnostics, inexpensive and biodegradable diagnostic products, chromogenic substrates, monoclonal antibodies, immunoassays, laboratory automation is estimated to radically change the Hemostasis diagnostics market over the following five years.

U.S. Beckman Coulter holds over half the U.S. market for Hematology devices

Key players operating in the market are HORIBA, Ltd., Abbott Laboratories, Siemens AG, and Bio-Rad Laboratories, Inc. The high and low-end analyzers provided by U.S. Beckman Coulter meet the needs of all hematology testing environment. Other vendors who have adopted ideal product models, business expansion and market appeal strategies are Becton, Dickinson & Company, Grifols S.A, Alere, Inc., F. Hoffmann-La Roche AG, Beckman Coulter Inc. Sekisui, Helena Labor, Chrono-Log, and Axis-Shield.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/hemostasis-diagnostics-market-434

Key Development

In February 2019, Horiba Medical, launched their new parameter, Yumizen D-Dimer, for its Yumizen G Hemostasis range of instruments to diagnose deep vein thrombosis and pulmonary embolism.

In 2017, Werfen and it's subsidiary Instrumentation Laboratory Company acquired Accriva Diagnostics, to expand leadership in point of care testing.

In 2016, Siemens Healthineers launched Sysmex CS-2500 a new mid-volume coagulation analyzer. Which enable labs to provide quality test results and achieve cost-effective method consolidation.

In 2015, Roche AG launched the new lab-coagulation solution, the cobas t 411 analyzer is lab coagulation system suitable for low volume routine testing (up to 120 samples per day), with this launch Roche AG expanded their diagnostic portfolio.

In 2014, Sysmex Corporation, launched LIASAUTO P-FDP hemostasis reagent for automated coagulation analyzers to determine the status of blood hyperfibrinolysis and hypercoagulable

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/434

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Hemostasis Diagnostics Market Share #Hemostasis Diagnostics Market

0 notes

market-research-future · 4 years ago

Text

Myasthenia Gravis Disease Market Profile, Segmentation, Vendor Landscape

Segmentation:

The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The imaging segment is classified into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.

On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous hematopoietic stem cell transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others. By medication, the market is divided into acetylcholinesterase inhibitors, immunosuppressants, steroids, and others. The acetylcholinesterase inhibitors segment is further classified into atropine, neostigmine, pyridostigmine, and others. Immunosuppressant drugs are further divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids segment is further divided into prednisone and others. Surgery is divided into thymectomy and others.

Request Free Sample Copy of the report “Myasthenia Gravis Disease Market Research Report – Forecast to 2023 ” at: https://www.marketresearchfuture.com/sample_request/5843

On the basis of end user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.

The global myasthenia gravis disease market is expected to exhibit a strong 7.5% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR).

Regional Analysis:

The global myasthenia gravis disease market is expected to be dominated by North America over the forecast period, with the Americas segment holding the dominant share in the market. The Americas market for myasthenia gravis disease is mainly driven by the growing awareness about the disease, as neurological diseases have been studied in detail in the region and awareness about this kind of disease is significantly high in the region. The growing demand for effective medications for neuromuscular diseases such as myasthenia gravis is likely to drive the drug development scenario in the Americas region over the forecast period, leading to steady growth of the myasthenia gravis disease market.

Europe holds the second largest share in the global myasthenia gravis disease market and is likely to remain a leading contender in the global market over the forecast period due to the growing awareness about neuromuscular conditions. Myasthenia gravis holds a significant position in the Europe market, as the disease can cause a significant burden on national healthcare systems. The increasing financial burden of myasthenia gravis disease is likely to drive the myasthenia gravis disease market in Europe over the forecast period.

Asia Pacific is likely to be a major regional market for myasthenia gravis disease over the forecast period due to the growing awareness about the disease and the increasing desire to eliminate the disease from urban populations in growing economies such as China, India, Japan, and South Korea. Increasing healthcare expenditure in the region is likely to be a major driver for the myasthenia gravis disease market over the forecast period. Rising awareness about neuromuscular diseases is likely to be a key driver for the myasthenia gravis disease market in Asia Pacific over the forecast period.

The Middle East and Africa is likely to retain a low share in the global myasthenia gravis disease market over the forecast period due to the lack of awareness about the disease in the region and the low disposable income of consumers in the region.

Competitive Analysis:

Leading players in the global myasthenia gravis disease market include Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Corporation, Novartis, Piramal Healthcare, Sun Pharmaceuticals Industries Ltd., and Valeant.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843

Research projects are likely to be crucial for the global myasthenia gravis disease market over the forecast period. In July 2019, a new case report from a man suffering from both multiple sclerosis and myasthenia gravis showed that the two diseases may share common autoimmune responses. In August 2019, a research team from Chongqing Medical University and SUNY Upstate Medical University found that gut microbes and metabolic changes could provide an accurate biomarker for myasthenia gravis disease. Such efforts are likely to remain crucial for the global myasthenia gravis disease market over the forecast period.

Browse Related Reports :

Live Cell Encapsulation Market Research Report - Forecast to 2023 | MRFR

Global Bariatric Surgery Market Size, Trends, Growth 2017-2023

Dietary Supplements in the Age of Personalized Nutrition Market Trends, Size, Share, Global Industry Forecast to 2023

About Market Research Future:

0 notes

medicaldevicetech · 4 years ago

Text

Spirometry Market Sees Promising Growth by 2023 According to New Research Report

Spirometry Market Overview:

The global spirometry market is expecting to touch a valuation of USD 1,106.46 million by 2023, according to Market Research Future (MRFR). The high prevalence of respiratory disorders is the major factor driving the market growth from 2018 to 2023 (forecast period). Rising cases of chronic obstructive pulmonary disorders (COPD), technological advances in respiratory care devices, and the expanding geriatric population are factors expected to spur market demand till 2023. As per a report by Asthma UK in 2016, nearly 1,410 people died from asthma.

Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/6539

Government initiatives to curtail smoking habits, focus on breathing diseases, rising levels of air pollution, and adoption of spirometers at homes are factors likely to augur market growth. Awareness of reimbursement policies among the public and clinicians are projected to drive patients towards taking these tests. But high costs of spirometers can act as a deterrent against market growth.

Spirometry Market Segmentation:

The spirometry market forecast can be segmented by product, technology, application, and end-user.

By product, the market is segmented into table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. The table-top spirometry segment accounted for 49.9% market share in 2017, followed by hand-held (31%), and desktop (19.1%). This can be attributed to adoption of spirometers in hospitals and clinics. But the desktop segment is touted to register the highest CAGR of 10.58% during the forecast period owing to its rapid diagnosis rate and increasing use of computer-based applications.

By technology, the market covers flow measurement spirometry, volume spirometry, and peak flow meters (PFM). The flow measurement spirometry segment accounted for 50.3% share in 2017. This can be attributed to its lightweight nature and compact size. Its functionality based on the familiar table-top spirometer technology and lack of frequent calibration make it popular among clinicians. But the PFM technology can register 10.58% CAGR over the forecast period to reach USD 149.76 million by 2023.

Major applications of the spirometry market include diagnostic and treatment monitoring. The diagnostic segment is further sub-segmented into asthma, interstitial pulmonary fibrosis, and COPD. The diagnostic segment accounted for 68.93% share of the market in 2017, spurred by the prevalence of breathing diseases such as asthma. But the treatment monitoring segment can exhibit the highest CAGR during the review period to reach a valuation of USD 353 million by 2023. Its valuation in 2018 was suggested to be USD 214.12 million.

Key market end-users include hospitals & clinics, research & academic institutes, diagnostic centers, and home care. The home care segment is projected to enjoy a 9.90% CAGR to reach a valuation of USD 71.14 million by 2023 from USD 44.38 million in 2018.

Spirometry Market Regional Analysis:

The spirometry market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas accounted for 39.74% share in the global market in 2017, followed by Europe and APAC. This can be attributed to economies such as the U.S. which are the earliest adopters of latest technologies coupled with the large patient pool suffering from respiratory disorders. The region is likely to enjoy a 10.25% CAGR over the forecast period.

The Europe spirometry market is expected to enjoy a CAGR similar to the Americas market over the forecast period to touch a valuation of USD 322.33 million by 2023. This can be credited to rising number of asthma cases and ballooned healthcare expenditure of nations such as Germany and France.

The MEA region can experience a respectable CAGR during the review period owing to improvements of healthcare infrastructure and enhanced healthcare budgets of Kuwait, Qatar, and Dubai.

The APAC region is expected to exhibit a 10.94% CAGR over the forecast period owing to high cases of chronic diseases, awareness of respiratory devices, and increased healthcare budgets of developed nations in the region. The growing geriatric populace in China and Japan can contribute to regional market revenue till 2023.

Spirometry Market Competitive Dashboard:

Key players in the spirometry market include Smiths Medical Inc. (U.S.), Vitalograph (U.K.), MGC Diagnostics Corporation (U.S.), Hill-Rom Holdings, Inc. (U.S.), Schiller AG (Switzerland), COSMED srl (Italy), Midmark Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Carefusion Corporation (U.S.), Nihon Kohden Corporation (Germany), and Koninklijke Philips N.V. (The Netherlands).

Access Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

List of Tables$

TABLE 1 MARKET SYNOPSIS

TABLE 2 LIST OF ASSUMPTIONS

TABLE 3 CPT CODE TEST DESCRIPTION (JANUARY 2018)

TABLE 4 ICD-9 CODES FOR SPIROMETRY

TABLE 5 GLOBAL SPIROMETRY MARKET, BY PRODUCT 2015-2023 (USD MILLION)

TABLE 6 GLOBAL SPIROMETRY MARKET FOR TABLE-TOP SPIROMETRY, BY REGION 2015-2023 (USD MILLION)

TABLE 7 GLOBAL SPIROMETRY MARKET FOR HAND-HELD SPIROMETRY, BY REGION 2015-2023 (USD MILLION)

TABLE 8 GLOBAL SPIROMETRY MARKET FOR DESKTOP (PC) SPIROMETRY, BY REGION 2015-2023 (USD MILLION)

TABLE 9 GLOBAL SPIROMETRY MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION)

TABLE 10 GLOBAL SPIROMETRY MARKET FOR FLOW MEASUREMENT SPIROMETRY, BY REGION 2015-2023 (USD MILLION)

TABLE 11 GLOBAL SPIROMETRY MARKET FOR PNEUMOTACHOGRAPH SYSTEM, BY REGION 2015-2023 (USD MILLION)

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: [email protected]

#Spirometry Market

0 notes

researchkraft19 · 4 years ago

Text

Pulmonary Function Testing Systems Market to Remain Lucrative During 2020-2027

Research Kraft has published the latest research report on the global Pulmonary Function Testing Systems market. The report helps in delivering key insights about the Pulmonary Function Testing Systems market and provides a competitive edge to the clients. The research study on the Pulmonary Function Testing Systems market includes all the detailed information on the current market situation supported by the historical records and also have analysis about the future market predictions. The report represents a 360 degree overview of the market and its key players.

Access PDF Sample Copy of the Report, Click here @ https://www.researchkraft.com/request-sample/1097643

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak.Understand the influence of COVID-19 on the Pulmonary Function Testing Systems Market Size with our analysts monitoring the situation across the globe.

The most significant players coated in global Pulmonary Function Testing Systems market report:

CareFusion(BD), Schiller, CHEST, COSMED, NDD, nSpire Health, MGC Diagnostics, Minato, M&B, AESRI, Ganshorn, Morgan Scientific, Sikeda, RSDQ

Major Types of Pulmonary Function Testing Systems covered are:

Portable PFT Systems

Complete PFT Systems

Major end-user applications for Pulmonary Function Testing Systems market:

Hospitals

Physical Examination Center

Physician Groups

Other Applications

Global Pulmonary Function Testing Systems Market Regional Analysis:

North America (U.S., Canada, Mexico) Europe (Germany, U.K., France, Italy, Russia, Spain, etc.) Asia-Pacific (China, India, Japan, Southeast Asia, etc.) South America (Brazil, Argentina, etc.) Middle East & Africa (South Africa, Saudi Arabia, etc.)

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here https://www.researchkraft.com/check-discount/1097643

Points Covered in The Report:

The major points considered in the Global Pulmonary Function Testing Systems Market report include the leading competitors operating in the global market.

The report also contains the company profiles of the players operating in the global market.

The manufacture, production, sales, future strategies, and the technological capabilities of the leading manufacturers are also included in the report.

The growth factors of the Global Pulmonary Function Testing Systems Market are explained in-depth, wherein the different end-users of the market are discussed precisely.

The report on the Global Pulmonary Function Testing Systems Market is a worthwhile source of information for every policymaker, investor, stakeholder, service provider, manufacturer, supplier, and player interested in purchasing this research document.

Access full Report Description, TOC, Table of Figure, Chart, etc. @https://www.researchkraft.com/send-an-enquiry/1097643

Research Kraft

Phone: 888-213-4282

Email: [email protected]

#Pulmonary Function Testing Systems Market

0 notes

jennielim · 4 years ago

Text

0 notes

lauramalchowblog · 5 years ago

Text

Rationale for Testing Anticoagulants Against COVID-19

By ETHAN WEISS, MD

We have seen and heard about the classic symptoms of COVID-19 at UCSF Medical Center, where I work as a cardiologist. Patients keep coming in with pulmonary distress, pneumonia, and ultimately, Acute Respiratory Distress Syndrome (ARDS) – the life-and-death situation that requires ventilators.

However, I’m beginning to learn about other symptoms that some doctors are noticing. There are numerous reports of other complications, especially in advanced disease.

One of the most interesting involves disruption of the blood’s coagulation system. New anecdotal reports have described clotting in test tubes and lines, derangements of clinical clotting assays, pulmonary emboli, large clots in the heart, as well as microvascular thrombosis.

Elevation in D-Dimer, (a biomarker of coagulation system activation) has been associated with dramatically increased risk of death from COVID-19. This has led some to speculate that empiric treatment with anticoagulants might improve outcomes in these critically ill patients. Indeed, there was this recent publication of a retrospective analysis of anticoagulation with heparin or low molecular weight heparin showing an association with improved outcomes in COVID-19 patients in China.

These are early observations, but they are coming from enough peers from different institutions that it makes me wonder if there could be a pattern. Clots, after all, are something we know how to treat, especially in an acute care setting.

Now let’s back up a little and think about what might be going on in the biology.

Hemostasis is defined as the arrest of bleeding by the physiological properties of vasoconstriction and coagulation (clotting). Thrombosis is defined as the formation of a thrombus: an aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements. A thrombus can be big trouble. They frequently cause vascular obstruction at the point of its formation, which can lead to heart attacks, strokes, and death.

There is a long history of association between systemic inflammatory states and infections and hemostasis and thrombosis. We��ve learned to look for certain well-established biomarkers like C-reactive protein, as early warning signals of systemic inflammation that can raise the risk of serious cardiovascular events. And there is a theory that the coagulation system itself evolved as an important component of the innate immune response. The system is highly regulated in both a positive and negative manner and must be tuned to respond rapidly to injury so as to prevent blood loss. But it must also be specific. Excessive clotting, when the patient isn’t suffering from an acute bleeding episode, can lead to rapid destruction of tissues and organs and death. This is accomplished via complex interactions between pro-coagulant molecules and anti-coagulant inhibitors as well as a finely-tuned system of molecules that dissolve clots (fibrinolysis). These all interface with cellular elements such platelets, endothelial cells and inflammatory cells. This delicate balance has been exploited by predators such as snakes. Their venom attacks important regulators of this highly regulated system to cause bleeding or clotting in their prey.

The relationship between inflammation and the coagulation system has been well-studied by Chuck Esmon at the University of Oklahoma Health Sciences Center and many others. Early work focused on the impact of inflammatory cytokines on increasing levels of pro-coagulant factors such as tissue factor and reducing anti-coagulant inhibitors such as activated protein C. Protein C levels are strongly impacted by overwhelming infectious conditions such as sepsis. Changes in protein C levels or function have been associated with adverse outcomes in patients with sepsis.

This led Esmon and colleagues to speculate that treatment with recombinant activated protein C might improve outcomes in sepsis. Early work in animals eventually led to the development of a clinical drug, Eli Lilly’s drotrecogin alfa (Xigris), which was eventually tested in a large randomized controlled trial, the PROWESS Trial, which showed reduced mortality but increased bleeding in patients with sepsis. Subsequent studies confirmed these results. The drug, lacking a compelling risk-benefit ratio, was pulled off the market in 2011.

Still, the learnings from those studies and others can be informative today. There is a well-explored link between the contact (intrinsic) pathway and inflammation. The contact pathway is activated by exposure to negatively charged molecules or polyphasphates and activation can lead to activation of the coagulation cascade via cleavage of Factor XI by Factor XIIa. Factor XIIa can also activate inflammatory pathways via release of bradykinin, a potent inflammatory mediator that causes blood vessels to dilate. While most of the work to date has focused on the effect of bacteria in activating the contact pathway, there is evidence that hantavirus can also activate the pathway and increase levels of bradykinin as well. Preclinical studies have supported the development of factor XIIa inhibitors for the treatment of sepsis.

It may be worth asking whether the new coronavirus might be acting along similar pathways as the hantavirus, triggering the release of inflammatory mediators that affect the coagulation cascade.

There have been many other attempts to modulate the coagulation system in severely ill patients with inflammation or systemic infections. The most notable of these was the APEX trial which compared extended use betrixaban (a novel oral factor Xa inhibitor marketed by Portola Pharmaceuticals as Bevyxxa) versus generic enoxaparin (a low molecular weight heparin anticoagulant) in medically ill patients. The results of this study, published in 2016, showed a 24% reduction in the primary efficacy outcome of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism in subjects treated with betrixaban versus enoxaparin in the whole study. There was a statistical trend toward benefit in a subset of patients with elevated levels of D-dimer. A recent analysis of the trial using D-dimers measured in a central lab showed significant improvement in patients with elevated D-dimer with a 31% risk reduction in the primary endpoint in those with D-Dimer ≥ 2 × upper limit of normal.

None of these clinical studies has explored the potential role of anticoagulants in viral infections. To date, there haven’t been large, randomized studies asking questions of this nature.

However, there is abundant evidence that severe viral infections also impact the coagulation system and can lead to increased morbidity and mortality. This was first described during the 2003 SARS outbreak (now called SARS-CoV-1). Comprehensive pathology studies demonstrated thrombus formation and fibrin deposition in small vessels and organs (so-called microvascular thrombosis). These studies suggest activation of the coagulation system, or perhaps diminished levels or activity of inhibitors. This was followed by a study showing the SARS-CoV-1 infection led to increases in levels of plasminogen activator inhibitor 1 (PAI1) in patients with SARS-CoV-1 compared to normal controls and patients with non-SARS pneumonias. PAI-1 is a serine protease inhibitor that inhibits the activity of multiple proteins in the hemostasis and thrombosis system, most notably tissue-type plasminogen activator (tPA). The traditional recombinant clot-buster, tPA activates the fibrinolytic system. Inhibiting tPA leads to less fibrin breakdown and increased clot burden. There was also an observed increase in the levels of vitronectin, which has been shown to be a co-factor for PAI-1 in inhibiting activated protein C (APC). While protein C levels or APC activity were not measured, this result suggested that SARS-CoV-1 infection could lead to a decrease in APC function and a functional pro-thrombotic state.

This brings us back to the clinical observations in patients with COVID-19. It is early and we have a lot to learn, but the clinical anecdotes suggest that SARS-CoV-2 may also impact the coagulation system as does SARS-CoV-1. And we certainly know that in advanced disease, there is marked elevation in inflammatory cytokines. What is most interesting is that there is now good evidence that the coagulation system is activated in severe medical illness including non-infectious illnesses. There is further evidence coagulation is activated in severe infections. Moreover, treatment with anticoagulant medications has improved outcomes in both severe medical illness and systemic infections. And there is good evidence that both SARS-CoV-1 and SARS-CoV-2 activate the coagulation cascade especially in the critically ill, leading to significant morbidity and mortality.

Given the nature of the illness and the prevalence of severe infections, now seems like the ideal time to perform rigorous clinical studies to explore the potential benefits/risks of drugs that modulate coagulation system activity in COVID-19. Questions as to which patients (perhaps those with modest or severe increases in D-Dimer) and which targets and which drugs remain to be answered. Such studies could enroll severely ill patients quickly at multiple centers around the world, and could conceivably yield statistically valid results on safety and efficacy in a matter of weeks. Based on what we know already about the underlying biology and the clinical need, there is clearly a very strong rationale to begin these studies as soon as possible.

Update (4/14/20):

Since publishing this just a week ago, there have been numerous developments in this rapidly moving field. I will not recount them exhaustively but will pick some highlights. First, I had previously missed this review of changes in coagulation markers in patients with COVID-19. Again we see dramatic changes especially with D-Dimer. Several recent studies put the prevalence of thrombotic complications in severe COVID-19 infections at 25 to 31% again with changes in coagulation markers (most notably D-Dimer). There was an autopsy series from New Orleans published in pre-print form showing prominent micro- and macro-vascular thrombosis with an interesting finding of the presence of megakaryocytes in the lungs. There was a small case report of 3 patients with severe COVID-19 infections and antiphospholipid antibodies and clinical thrombosis (all intra-cerebral).

Lastly, the International Society of Thrombosis and Hemostasis (ISTH) published guidance suggesting anticoagulating all hospitalized patients with COVID-19. And of course there continue to be anecdotes of doctors experimenting with many therapies for sick COVID patients with thrombosis including this story of the use of tPA. I will try to continue to update regularly.

Ethan Weiss, MD is an Associate Professor of Medicine at UCSF, is a Preventive Cardiologist, and is a Core Investigator at the Cardiovascular Research Institute.

This article originally appeared on the Timmerman Report here.

The post Rationale for Testing Anticoagulants Against COVID-19 appeared first on The Health Care Blog.

Rationale for Testing Anticoagulants Against COVID-19 published first on https://venabeahan.tumblr.com

0 notes

kristinsimmons · 5 years ago

Text

Rationale for Testing Anticoagulants Against COVID-19

By ETHAN WEISS, MD

However, I’m beginning to learn about other symptoms that some doctors are noticing. There are numerous reports of other complications, especially in advanced disease.

Now let’s back up a little and think about what might be going on in the biology.

There is a long history of association between systemic inflammatory states and infections and hemostasis and thrombosis. We’ve learned to look for certain well-established biomarkers like C-reactive protein, as early warning signals of systemic inflammation that can raise the risk of serious cardiovascular events. And there is a theory that the coagulation system itself evolved as an important component of the innate immune response. The system is highly regulated in both a positive and negative manner and must be tuned to respond rapidly to injury so as to prevent blood loss. But it must also be specific. Excessive clotting, when the patient isn’t suffering from an acute bleeding episode, can lead to rapid destruction of tissues and organs and death. This is accomplished via complex interactions between pro-coagulant molecules and anti-coagulant inhibitors as well as a finely-tuned system of molecules that dissolve clots (fibrinolysis). These all interface with cellular elements such platelets, endothelial cells and inflammatory cells. This delicate balance has been exploited by predators such as snakes. Their venom attacks important regulators of this highly regulated system to cause bleeding or clotting in their prey.

It may be worth asking whether the new coronavirus might be acting along similar pathways as the hantavirus, triggering the release of inflammatory mediators that affect the coagulation cascade.

None of these clinical studies has explored the potential role of anticoagulants in viral infections. To date, there haven’t been large, randomized studies asking questions of this nature.

Update (4/14/20):

Ethan Weiss, MD is an Associate Professor of Medicine at UCSF, is a Preventive Cardiologist, and is a Core Investigator at the Cardiovascular Research Institute.

This article originally appeared on the Timmerman Report here.

The post Rationale for Testing Anticoagulants Against COVID-19 appeared first on The Health Care Blog.

Rationale for Testing Anticoagulants Against COVID-19 published first on https://wittooth.tumblr.com/

0 notes